Clinical trials: Immune System Disorder (Healthy Volunteer)
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Healthy Participants
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in…
- Trial name
- NCT06723756
- Testing
- Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
HIV Infections
Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
The purpose of this clinical research study is to assess the effect of Atazanavir 400 mg QD and Atazanavir/Ritonavir 300/100 mg QD at steady state on the single dose pharmacokinetics of RGZ in healthy subjects.
- Trial name
- NCT00362726
- Testing
- Rosiglitazone maleate, Atazanavir Sulphate, Atazanavir Sulphate + Rosiglitazone maleate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Immunity Disorders
Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants
A Phase IV, open-label, adaptive, 4-arm, multi-dose, single-centre, exploratory trial to assess the immune diversity response to oral administration of licensed Natural Health Products, in healthy adults, 60-70 years of age.
- Trial name
- NCT05242718
- Testing
- N-Acetyl-L-cysteine (NAC), Echinacea purpurea, Curcumin
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Immunoflex Therapeutics Inc.
HIV Infections, Acquired Immune Deficiency Syndrome
Reactogenicity and Immunogenicity of Vaginal CNgp140
To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.
- Trial name
- SG06RS02 (NCT00637962)
- Testing
- HIV glycoprotein CN54gp140 (vaccine), Carbopol 974
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Systemic Lupus Erythematosus
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects.
- Trial name
- NCT06657703
- Testing
- HC022
- Where
- 3 sites in China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HC Biopharma Inc.
Asthma
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.
- Trial name
- NCT00192296
- Testing
- MEDI-528 0.3 mg/kg, MEDI-528 1 mg/kg, MEDI-528 3 mg/kg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis
Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple…
- Trial name
- NCT06038279
- Testing
- INI-2004
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Inimmune Corporation
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Peanut Allergies
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake.
- Trial name
- NCT07287033
- Testing
- MY006 Low Dose, MY006 Mid Dose, MY006 High Dose
- Where
- 9 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabylon AG
Asthma, Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366
CHF6366 is a novel bifunctional compound displaying both muscarinic receptor antagonist and β2-adrenergic receptor agonist properties (MABA), with the potential to deliver optimal bronchodilation after inhalation dosing via two…
- Trial name
- NCT03378648
- Testing
- CHF6366, umeclidinium bromide and vilanterol trifenatate
- Where
- United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)
The purpose of this study is to demonstrate dose proportionality of the FF (50 microgram (mcg), 100 mcg or 200 mcg), when administered as a single and repeat dose from the NDPI containing FF formulated with lactose.
- Trial name
- NCT01669070
- Testing
- FF, 50 mcg, FF, 100 mcg, FF, 200 mcg
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Glycemic and Insulinemic Response, Type 1 Diabetes (T1D)
Glycemic Response to Carbob-Enriched Pasta in Healthy and With Type 1 Diabetes People
Carob (Ceratonia siliqua) is a fruit traditionally used in various Mediterranean countries for the preparation of sweets and beverages.
- Trial name
- GR-CEP (NCT06994403)
- Testing
- Durum wheat pasta enriched with carob flour, Standard durum wheat pasta, White bread reference meal
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Federico II University
Healthy
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and…
- Trial name
- NCT01290211
- Testing
- Maraviroc, Fosamprenavir/ritonavir, Maraviroc + Fosamprenavir/ritonavir
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Immune System Disorder, Healthy Volunteers
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects
The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance…
- Trial name
- NCT05806567
- Testing
- Belumosudil, UGT1A1 victim drug, P-gp victim drug
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Healthy Volunteers, Diabetes Mellitus, Type 1
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
This study is investigating the safety and tolerability of the new investigational product NNC0363-0845, its concentrations in the blood and its effect on the blood sugar for the treatment of diabetes.
- Trial name
- NCT04569994
- Testing
- NNC0363-0845, Insulin degludec
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart.
- Trial name
- NCT00887770
- Testing
- AZD5672, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV-1
TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
The purpose of this study is: to determine the safety, (local) tolerability and plasma exposure over time of single intramuscular (IM) doses of 600 and 1200 mg of a new formulation (F006) of TMC278LA, to determine the safety…
- Trial name
- NCT00741741
- Testing
- TMC278
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.